Furthermore, we observed RAFi-driven activation of GCN2-ISR in tumour cells with wild type BRAF, mutant BRAF, mutant KRAS and immortalised MEFs with no ERK pathway mutation. This evidence concerns the gene KRAS and neoplasm.